newsfilter
← Earnings
Earnings Releases·

RenovoRx — Third Quarter 2026 Earnings Summary

  • Revenue reached $1.07 million, reflecting a nearly 300% year-over-year increase and 17% sequential growth, while gross margin expanded to approximately 82% from 80% in the prior year period.
  • Full-year 2026 revenue guidance remains unchanged at $3.75 million to $4.25 million, implying 241% to 286% year-over-year growth, with management projecting cash resources sufficient to fund operations through the second half of 2027.
  • The company achieved record operational milestones including full enrollment of the Phase III TIGeR-PaC trial in August 2026, receipt of a Notice of Allowance for a new patent, and expansion of the commercial funnel to over 65 centers.
  • Cash and cash equivalents increased to $10.4 million, driven by $3.5 million in proceeds from warrant exercises, while the company targets 36 active commercial cancer centers by the end of 2026.
Company
RENOVORX INC
Sector
Healthcare
Industry
Biotechnology